MDACC Study No:2007-0213 ( NCT No: NCT00632359)
Title:A Study of Lenalidomide in Patients with Chronic Lymphocytic Leukemia and Residual Disease after Chemotherapy - RV-CLL-PI-0270
Principal Investigator:Alessandra Ferrajoli
Treatment Agent:Lenalidomide
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if RevlimidTM
(lenalidomide) can help to reduce the level of leukemia in your body. The
safety of this drug will also be studied.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Lenalidomide
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:None
Supported By:Celgene Corporation, Inc.
Return Visit:Initial evaluation, month 4, 12 and every 3 months thereafter while on study.
Home Care:None

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Alessandra Ferrajoli
For Clinical Trial Enrollment:713-792-2063
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults